Artificial Pancreas Device Systems Market To Reach $981.0 Million By 2030

Artificial Pancreas Device Systems Market Growth & Trends

The global artificial pancreas device systems market size is expected to reach USD 981.0 million by 2030, registering a CAGR of 18.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing geriatric population, growing incidence of diabetes, and the rising prevalence of obesity are the major factors driving the market growth. In addition, industry players are developing new advanced technologies to provide better compliance and integration with IT devices, which is contributing to the market growth.

The outbreak of COVID-19 in the year 2020 has positively impacted the artificial pancreas device systems market, growth owing to the need for diabetes management in COVID-19 patients. Moreover, COVID-19 recovered diabetes patients have developed resistance to insulin, and the traditional injections fail to provide proper management. Artificial pancreas device systems (APDS) can replace the need for frequent sugar level checks and control blood glucose levels. These factors are anticipated to create huge growth opportunities for market players during the forecast period.

Moreover, regulatory bodies such as FDA are continuously approving new and innovative products, thus increasing the reach of the companies in various markets. For instance, in June 2017, Medtronic launched its latest artificial pancreas system in the U.S. market. This device is capable of automatically delivering insulin to patients when they need it. Similarly, in May 2019, Beta Bionics, Inc. & Zealand Pharma initiated an in-home trial of the iLet Bionic Pancreas system, a dual-hormone pump system intended to automatically deliver dasiglucagon and insulin.

 Request a free sample copy or view report summary: Artificial Pancreas Device Systems Market Report

Artificial Pancreas Device Systems Market Highlights

• Based on device type, Threshold suspend device systems dominated the market and accounted for a share of 73.8% in 2023 mainly due to these systems offering safety features by automatically suspending insulin delivery when glucose levels fall below a threshold, reducing the risk of hypoglycemia.

• The Control-to-Target (CTT) systems segment is expected to register the fastest CAGR of 21.3 % over the forecast period attributed to a more advanced and accurate approach to glucose management.

• North America artificial pancreas device systems market dominated with a share of 45.8% in 2023. The high prevalence of diabetes in the region, advanced healthcare infrastructure, patient awareness, and increasing investments in research and development under public-private partnerships boost regional developments.

Artificial Pancreas Device Systems Market Segmentation

Grand View Research has segmented the global artificial pancreas device systems market on the basis of on device type and region:

Artificial Pancreas Device Systems Device Type Outlook (Revenue, USD Million, 2018 - 2030)

• Threshold Suspend Device Systems

• Control-to-Range (CTR) Systems

• Control-to-Target (CTT) Systems

Artificial Pancreas Device Systems Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

  • Colombia

• Middle East and Africa (MEA)

  • UAE

  • South Africa

  • Saudi Arabia

List Of Key Players in the Artificial Pancreas Device Systems Market

• Medtronic Plc

• Bigfoot Biomedical

• Tandem Diabetes Care, Inc.

• Pancreum, Inc.

• TypeZero Technologies, LLC

• Beta Bionics